2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Blood plasma infusions for Parkinson’s
Blood plasma may have beneficial effects in neurodegenerative conditions, including Parkinson’s.
Parkinson’s: The absence of appendixes and tonsils
Researchers in Stockholm have recently published a report indicating that the removal of the appendix or tonsils could reduce a person’s risk of developing Parkinson’s.
Astrocytes to dopamine neurons in one step
The brain is made up of multiple types of cells. There are the neurons that conduct much of the cognitive functioning in the brain, Then there are a collection of supportive helper cells which include astrocytes and microglia.
Phase 1 results for a Parkinson’s vaccine
Austrian biotech company AFFiRiS have published the results of their phase l clinical trial testing the safety and tolerability of a vaccine treatment for Parkinson’s.
A greater role for the parkinson’s GBA gene protein?
There is a great deal of variability between each person affected by Parkinson’s. Better knowledge of these variables could not only provide insights into the underlying biology of Parkinson’s but could also help us understand how best to treat it.